Journal
TRENDS IN BIOTECHNOLOGY
Volume 33, Issue 8, Pages 449-461Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tibtech.2015.05.001
Keywords
-
Categories
Funding
- Boston University Cross-disciplinary Training in Nanotechnology for Cancer (XTNC) Program
- National Institutes of Helath [DP2CA186574]
- Boston University College of Engineering
Ask authors/readers for more resources
The adoptive transfer of genetically engineered T cells with cancer-targeting receptors has shown tremendous promise for eradicating tumors in clinical trials. This form of cellular immunotherapy presents a unique opportunity to incorporate advanced systems and synthetic biology approaches to create cancer therapeutics with novel functions. We first review the development of synthetic receptors, switches, and circuits to control the location, duration, and strength of T cell activity against tumors. In addition, we discuss the cellular engineering and genome editing of host cells (or the chassis) to improve the efficacy of cell-based cancer therapeutics, and to reduce the time and cost of manufacturing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available